{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:05:27Z","timestamp":1789646727196,"version":"4.0.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"DOI":"10.1007\/s00347-026-02530-9","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:58:13Z","timestamp":1789646293000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Topisches Atropin zur Myopiepr\u00e4vention","Topical atropine for myopia prevention"],"prefix":"10.1007","author":[{"given":"Isabella Silke Elisabeth","family":"Gross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4409-2176","authenticated-orcid":false,"given":"Navid","family":"Farassat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"2530_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-086698","volume":"393","author":"A Azuara-Blanco","year":"2026","unstructured":"Azuara-Blanco\u00a0A, Logan\u00a0NS, McConnell\u00a0E et\u00a0al (2026) Low concentration atropine eye drops and progression of myopia in children: multicentre, double-masked, randomised trial (CHAMP-UK). BMJ 393:e086698","journal-title":"BMJ"},{"key":"2530_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100923","volume":"83","author":"NA Brennan","year":"2021","unstructured":"Brennan\u00a0NA, Toubouti\u00a0YM, Cheng\u00a0X et\u00a0al (2021) Efficacy in myopia control. Prog Retin Eye Res 83:100923","journal-title":"Prog Retin Eye Res"},{"key":"2530_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/opo.13058","volume":"43","author":"MA Bullimore","year":"2023","unstructured":"Bullimore\u00a0MA, Brennan\u00a0NA (2023) Myopia: An ounce of prevention is worth a\u00a0pound of cure. Ophthalmic Physiol Opt 43:116\u2013121","journal-title":"Ophthalmic Physiol Opt"},{"key":"2530_CR4","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","volume":"119","author":"A Chia","year":"2012","unstructured":"Chia\u00a0A, Chua\u00a0WH, Cheung\u00a0YB et\u00a0al (2012) Atropine for the treatment of childhood myopia: safety and efficacy of 0.5\u202f%, 0.1\u202f%, and 0.01\u202f% doses. Ophthalmology 119:347\u2013354","journal-title":"Ophthalmology"},{"key":"2530_CR5","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","volume":"113","author":"WH Chua","year":"2006","unstructured":"Chua\u00a0WH, Balakrishnan\u00a0V, Chan\u00a0YH et\u00a0al (2006) Atropine for the treatment of childhood myopia. Ophthalmology 113:2285\u20132291","journal-title":"Ophthalmology"},{"key":"2530_CR6","first-page":"139","volume":"2","author":"H Derby","year":"1874","unstructured":"Derby\u00a0H (1874) On the Atropine Treatment of Acquired and Progressive Myopia. Trans Am Ophthalmol Soc 2:139\u2013154","journal-title":"Trans Am Ophthalmol Soc"},{"key":"2530_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-068822","volume":"13","author":"N Farassat","year":"2023","unstructured":"Farassat\u00a0N, B\u00f6hringer\u00a0D, K\u00fcchlin\u00a0S et\u00a0al (2023) Low-dose AtropIne for Myopia Control in Children (AIM): protocol for a randomised, double-blind, multicentre trial. BMJ Open 13:e068822","journal-title":"BMJ Open"},{"key":"2530_CR8","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1136\/bjo-2024-326852","volume":"109","author":"N Guemes-Villahoz","year":"2025","unstructured":"Guemes-Villahoz\u00a0N, Talavero Gonz\u00e1lez\u00a0P, Porras-\u00c1ngel\u00a0P et\u00a0al (2025) Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month RCT for myopia control using DIMS lenses and 0.025\u202f% atropine. Br J Ophthalmol 109:1074\u20131080","journal-title":"Br J Ophthalmol"},{"key":"2530_CR9","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ophtha.2021.10.016","volume":"129","author":"A Ha","year":"2022","unstructured":"Ha\u00a0A, Kim\u00a0SJ, Shim\u00a0SR et\u00a0al (2022) Efficacy and Safety of 8 Atropine Concentrations for Myopia Control in Children: A Network Meta-Analysis. Ophthalmology 129:322\u2013333","journal-title":"Ophthalmology"},{"key":"2530_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14020175","volume":"14","author":"NC Hansen","year":"2024","unstructured":"Hansen\u00a0NC, Hvid-Hansen\u00a0A, M\u00f8ller\u00a0F et\u00a0al (2024) Two-Year Results of 0.01\u202f% Atropine Eye Drops and 0.1\u202f% Loading Dose for Myopia Progression in Danish Children. J\u00a0Pers Med 14:175","journal-title":"J Pers Med"},{"key":"2530_CR11","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s10792-021-01755-8","volume":"41","author":"L Joachimsen","year":"2021","unstructured":"Joachimsen\u00a0L, Farassat\u00a0N, Bleul\u00a0T et\u00a0al (2021) Side effects of topical atropine 0.05\u202f% compared to 0.01\u202f% for myopia control in German school children: a\u00a0pilot study. Int Ophthalmol 41:2001\u20132008","journal-title":"Int Ophthalmol"},{"key":"2530_CR12","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.62.5.6","volume":"62","author":"JB Jonas","year":"2021","unstructured":"Jonas\u00a0JB, Ang\u00a0M, Cho\u00a0P et\u00a0al (2021) IMI Prevention of Myopia and Its Progression. Invest Ophthalmol Vis Sci 62:6","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2530_CR13","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/OPX.0000000000001884","volume":"99","author":"JH Jones","year":"2022","unstructured":"Jones\u00a0JH, Mutti\u00a0DO, Jones-Jordan\u00a0LA et\u00a0al (2022) Effect of Combining 0.01\u202f% Atropine with Soft Multifocal Contact Lenses on Myopia Progression. Optom Vis Sci 99:434\u2013442","journal-title":"Optom Vis Sci"},{"key":"2530_CR14","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s40123-026-01341-0","volume":"15","author":"M Korenfeld","year":"2026","unstructured":"Korenfeld\u00a0M, Hurcikova\u00a0M, Tatsuoka\u00a0K et\u00a0al (2026) STudy of Atropine to Reduce (STAR) Myopia Progression: 24-Month Results. Ophthalmol Ther 15:1685\u20131703","journal-title":"Ophthalmol Ther"},{"key":"2530_CR15","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/ceo.14148","volume":"50","author":"SS Lee","year":"2022","unstructured":"Lee\u00a0SS, Lingham\u00a0G, Blaszkowska\u00a0M et\u00a0al (2022) Low-concentration atropine eyedrops for myopia control in Australian children. Clin Exp Ophthalmol 50:1001\u20131012","journal-title":"Clin Exp Ophthalmol"},{"key":"2530_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2026.1786718","volume":"13","author":"Y Li","year":"2026","unstructured":"Li\u00a0Y, Yi\u00a0M, Liu\u00a0B (2026) Efficacy of orthokeratology combined with atropine versus orthokeratology alone for myopia control in children: a\u00a0meta-analysis. Front Med 13:1786718","journal-title":"Front Med"},{"key":"2530_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1001\/jamaophthalmol.2023.5467","volume":"142","author":"Y Li","year":"2024","unstructured":"Li\u00a0Y, Yip\u00a0M, Ning\u00a0Y et\u00a0al (2024) Topical Atropine for Childhood Myopia Control: The ATLAS Study. JAMA Ophthalmol 142:15\u201323","journal-title":"JAMA Ophthalmol"},{"key":"2530_CR18","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41433-026-04478-1","volume":"40","author":"G Lingham","year":"2026","unstructured":"Lingham\u00a0G, Loughman\u00a0J, Lee\u00a0SS et\u00a0al (2026) Low-concentration atropine for management of myopia progression: does iris colour matter? Eye 40:1499\u20131506","journal-title":"Eye"},{"key":"2530_CR19","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1111\/aos.15761","volume":"102","author":"J Loughman","year":"2024","unstructured":"Loughman\u00a0J, Kobia-Acquah\u00a0E, Lingham\u00a0G et\u00a0al (2024) Myopia outcome study of atropine in children: Two-year result of daily 0.01\u202f% atropine in a\u00a0European population. Acta Ophthalmol 102:e245\u2013e256","journal-title":"Acta Ophthalmol"},{"key":"2530_CR20","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1001\/jamaophthalmol.2024.5703","volume":"143","author":"J Loughman","year":"2025","unstructured":"Loughman\u00a0J, Lingham\u00a0G, Nkansah\u00a0EK et\u00a0al (2025) Efficacy and Safety of Different Atropine Regimens for Myopia: 3\u2011Year MOSAIC Results. JAMA Ophthalmol 143:134\u2013144","journal-title":"JAMA Ophthalmol"},{"key":"2530_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0281816","volume":"18","author":"P Nucci","year":"2023","unstructured":"Nucci\u00a0P, Lembo\u00a0A, Schiavetti\u00a0I et\u00a0al (2023) A comparison of myopia control in European children with DIMS spectacles, atropine, and combined DIMS\/atropine. PLoS One 18:e0281816","journal-title":"PLoS One"},{"key":"2530_CR22","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/jamaophthalmol.2023.2855","volume":"141","author":"MX Repka","year":"2023","unstructured":"Repka\u00a0MX, Weise\u00a0KK, Chandler\u00a0DL et\u00a0al (2023) Low-Dose 0.01\u202f% Atropine Eye Drops vs Placebo for Myopia Control: A\u00a0Randomized Clinical Trial. JAMA Ophthalmol 141:756\u2013765","journal-title":"JAMA Ophthalmol"},{"key":"2530_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/ICL.0000000000000932","volume":"48","author":"K Richdale","year":"2022","unstructured":"Richdale\u00a0K, Tomiyama\u00a0ES, Novack\u00a0GD et\u00a0al (2022) Compounding of Low-Concentration Atropine for Myopia Control. Eye Contact Lens 48:489\u2013492","journal-title":"Eye Contact Lens"},{"key":"2530_CR24","unstructured":"Schr\u00f6der\u00a0C (1874) Ueber Atropinkuren gegen Kurzsichtigkeit. Z Augenheilkd"},{"key":"2530_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/ICL.0000000000000677","volume":"46","author":"A Upadhyay","year":"2020","unstructured":"Upadhyay\u00a0A, Beuerman\u00a0RW (2020) Biological Mechanisms of Atropine Control of Myopia. Eye Contact Lens 46:129\u2013135","journal-title":"Eye Contact Lens"},{"key":"2530_CR26","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/opo.13115","volume":"43","author":"E van der Sande","year":"2023","unstructured":"van der Sande\u00a0E, Polling\u00a0JR, Tideman\u00a0JWL et\u00a0al (2023) Myopia control in Mendelian forms of myopia. Ophthalmic Physiol Opt 43:494\u2013504","journal-title":"Ophthalmic Physiol Opt"},{"key":"2530_CR27","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ophtha.2021.10.002","volume":"129","author":"JC Yam","year":"2022","unstructured":"Yam\u00a0JC, Zhang\u00a0XJ, Zhang\u00a0Y et\u00a0al (2022) Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP): Phase 3 Report. Ophthalmology 129:308\u2013321","journal-title":"Ophthalmology"},{"key":"2530_CR28","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1001\/jama.2022.24162","volume":"329","author":"JC Yam","year":"2023","unstructured":"Yam\u00a0JC, Zhang\u00a0XJ, Zhang\u00a0Y et\u00a0al (2023) Effect of Low-Concentration Atropine Eyedrops vs. Placebo on Myopia Incidence in Children: The LAMP2 Randomized Clinical Trial. JAMA 329:472\u2013481","journal-title":"JAMA"},{"key":"2530_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/ICL.0000000000001154","volume":"51","author":"HR Yum","year":"2025","unstructured":"Yum\u00a0HR, Han\u00a0SY, Park\u00a0SH, Shin\u00a0SY (2025) Synergistic Effect of Dual-Focus Soft Contact Lenses and 0.05\u202f% Atropine on Myopia Control in Children. Eye Contact Lens 51:92\u201397","journal-title":"Eye Contact Lens"},{"key":"2530_CR30","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jamaophthalmol.2023.2097","volume":"141","author":"K Zadnik","year":"2023","unstructured":"Zadnik\u00a0K, Schulman\u00a0E, Flitcroft\u00a0I et\u00a0al (2023) Efficacy and Safety of 0.01\u202f% and 0.02\u202f% Atropine for Pediatric Myopia Progression Over\u00a03 Years. JAMA Ophthalmol 141:990\u2013999","journal-title":"JAMA Ophthalmol"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-026-02530-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-026-02530-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-026-02530-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:58:17Z","timestamp":1789646297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-026-02530-9"}},"subtitle":["Aktuelle Studienlage","Current study situation"],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":30,"alternative-id":["2530"],"URL":"https:\/\/doi.org\/10.1007\/s00347-026-02530-9","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"30 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.S.E.\u00a0Gross gibt an, dass kein Interessenkonflikt besteht. N.\u00a0Farassat ist als Berater in Scientific Advisory Boards der Firma Santen t\u00e4tig.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}